A Controlled Study of the Efficacy of Pentylenetetrazol (Metrazol) with Hard-Core Hospitalized Psychogeriatric Patients
Abstract
An 18-week double-blind crossover study of 61 "hard core" geriatric patients with organic brain syndrome compared the efficacy of pentylenetetrazol (Metrazol) with placebo, using a dosage level of 600 mg. per day. Five rating instruments were administered at the beginning, the crossover point, and the end of the study. The results demonstrated no superiority of Metrazol over placebo. Women improved more than men under both conditions. The sequence of administration of medications was not significant. Side effects were noted in only 15 percent of patients on Metrazol and eight percent on placebo.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
